Patents by Inventor Kenneth M. Boy

Kenneth M. Boy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gamma-lactams as beta-secretase inhibitors
    Patent number: 7388007
    Abstract: There is provided a series of novel substituted gamma-lactams of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R4, R5 and R6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.
    Type: Grant
    Filed: August 18, 2005
    Date of Patent: June 17, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lorin A. Thompson, III, Kenneth M. Boy, Jianliang Shi, John E. Macor
  • N-Aryl Pyrrolidine Derivatives as Beta-Secretase Inhibitors
    Publication number: 20070232679
    Abstract: There is provided a series of substituted N-aryl pyrrolidine derivatives of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R5?, R6, R7, and p as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.
    Type: Application
    Filed: March 29, 2007
    Publication date: October 4, 2007
    Inventors: Kenneth M. Boy, Shirong Zhu, John E. Macor, Shuhao Shi, Samuel Gerritz
  • 2-aryl thiazole derivatives as KCNQ modulators
    Patent number: 7273866
    Abstract: Novel 2-arylthiazole derivatives of Formula I are described which are openers of KCNQ potassium channels and are useful in the treatment of disorders that are responsive to the opening of the KCNQ potassium channels, including pain and migraine
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: September 25, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Yong-Jin Wu, Jason M. Guernon
  • 3-thia-4-arylquinolin-2-one derivatives
    Patent number: 7179920
    Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: February 20, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Piyasena Hewawasam, Sing-Yuen Sit
  • Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus
    Patent number: 7173004
    Abstract: Macrocyclic isoquinoline peptides are disclosed having the general formula: A compound of formula I: wherein R1 to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: February 6, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Fiona McPhee, Jeffrey Allen Campbell, Stanley D'Andrea, Zhizhen Barbara Zheng, Andrew Charles Good, David J. Carini, Barry L. Johnson, Paul Michael Scola, Kenneth M. Boy
  • 3-thia-4-arylquinolin-2-one derivatives
    Patent number: 7145013
    Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: December 5, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventor: Kenneth M. Boy
  • Compounds for the treatment of male erectile dysfunction
    Patent number: 7132542
    Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: November 7, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventor: Kenneth M. Boy
  • 3-Thia-4-arylquinolin-2-one potassium channel modulators
    Patent number: 7049309
    Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: May 23, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Piyasena Hewawasam, Sing-Yuen Sit, Kai Xie
  • 3-Thia-4-arylquinolin-2-one derivatives as smooth muscle relaxants
    Patent number: 7002015
    Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: February 21, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventor: Kenneth M. Boy
  • Aminoalkyl thiazole derivatives as KCNQ modulators
    Patent number: 6933308
    Abstract: Novel aminoalkylthiazole derivatives of Formula I are described which are openers of KCNQ potassium channels and are useful in the treatment of disorders responsive to the opening of the KCNQ potassium channels, including pain and migraine.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: August 23, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Yong-Jin Wu
  • 2-aryl thiazole derivatives as KCNQ modulators
    Publication number: 20040147401
    Abstract: Novel 2-arylthiazole derivatives of Formula I are described which are openers of KCNQ potassium channels and are useful in the treatment of disorders that are responsive to the opening of the KCNQ potassium channels, including pain and migraine.
    Type: Application
    Filed: December 9, 2003
    Publication date: July 29, 2004
    Inventors: Kenneth M. Boy, Yong-Jin Wu, Jason M. Guernon
  • Aminoalkyl thiazole derivatives as KCNQ modulators
    Publication number: 20040138268
    Abstract: Novel aminoalkylthiazole derivatives of Formula I are described which are openers of KCNQ potassium channels and are useful in the treatment of disorders responsive to the opening of the KCNQ potassium channels, including pain and migraine.
    Type: Application
    Filed: December 9, 2003
    Publication date: July 15, 2004
    Inventors: Kenneth M. Boy, Yong-Jin Wu